Gene Expression Patterns in Hepatic Tissue and Visceral Adipose Tissue of Patients with Non-Alcoholic Fatty Liver Disease
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Non-alcoholic fatty liver disease (NAFLD) and its progressive form, non-alcoholic steatohepatitis (NASH), are among the least understood metabolic consequences of obesity. Increasingly, omental adipose tissue is recognized as a biologically active organ in the pathogenesis of NAFLD. Differences in transcriptional regulation in omental adipose tissue and liver tissue may provide important insights into the pathogenesis of NAFLD and its progression.
Transcriptional profiles were obtained for liver and visceral adipose specimens of morbidly obese patients undergoing bariatric surgery. Functional analyses with the Ingenuity Pathways Knowledge Base (IPKB) and IPA 4.0 software identified genes that potentially play hepatoprotective roles as well as those potentially involved in the pathogenesis of NASH.TNF〈 and IL6 were measured in the serum samples.
Tissue from patients with NASH showed prominent adipose-specific deregulation of genes related to inflammation and the immune system. A number of liver and adipose-specific functional networks, including those centered at TNF〈, JUN/JUNB, and IFN© were highlighted as related to the NASH pathogenesis.The results also showed compensatory increases in hepatic detoxification enzymes and decreases in the gene network controlled by transcription factor COUP-TFII.
Our findings support the hypothesis that adipocyte secretion plays an important role in the development of NAFLD.
- Bray GA. Medical consequences of obesity. J Clin Endocrinol Metab 2004; 89: 2583–9. CrossRef
- Matteoni CA, Younossi ZM, Gramlich T et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116: 1413–9. CrossRef
- Falck-Ytter Y, Younossi ZM, Marchesini G et al. Clinical features and natural history of nonalcoholic steatosis syndromes. Semin Liver Dis 2001; 21: 17–26. CrossRef
- Ong JP, Elariny H, Collantes R et al. Predictors of nonalcoholic steatohepatitis and advanced fibrosis in obese patients. Obes Surg 2005; 15: 310–5. CrossRef
- Clark JM. The epidemiology of nonalcoholic fatty liver disease in adults. J Clin Gastroenterol 2006; 40: S5–S10.
- Zelber-Sagi S, Nitzan-Kaluski D, Halpern Z et al. Prevalence of primary non-alcoholic fatty liver disease in a population-based study and its association with biochemical and anthropometric measures. Liver Int 2006; 26: 856–63. CrossRef
- Younossi ZM, Diehl AM, Ong JP. Nonalcoholic fatty liver disease: an agenda for clinical research. Hepatology 2002; 35: 746–52. CrossRef
- Chitturi S, Farrell GC. Etiopathogenesis of nonalcoholic steatohepatitis. Semin Liver Dis 2001; 21: 27–41. CrossRef
- Te Sligte K, Bourass I, Sels JP et al. Non-alcoholic steatohepatitis: review of a growing medical problem. Eur J Intern Med 2004; 15: 10–21. CrossRef
- Schaffler A, Scholmerich J, Buchler C. Mechanisms of disease: adipocytokines and visceral adipose tissue – emerging role in nonalcoholic fatty liver disease. Nat Clin Pract Gastroenterol Hepatol 2005; 2: 273–80. CrossRef
- Choi S, Diehl AM. Role of inflammation in nonalcoholic steatohepatitis. Curr Opin Gastroenterol 2005; 21: 702–7. CrossRef
- Younossi ZM, Gorreta F, Ong J et al. Hepatic gene expression in patients with obesity-related non-alcoholic steatohepatitis. Liver Int 2005; 25: 760–71. CrossRef
- Baranova A, Collantes R, Gowder S et al. Obesity-related differential gene expression in the visceral adipose tissue. Obes Surg 2005; 15: 58–65. CrossRef
- Younossi ZM, Baranova A, Ziegler K et al. A genomic and proteomic study of the spectrum of nonalcoholic fatty liver disease. Hepatology 2005; 42: 665–74. CrossRef
- Baranova A, Gowder S, Naouar S et al. Expression profile of ovarian tumors: distinct signature of Sertoli-Leydig cell tumor. Int J Gyn Cancer 2006; 16:1963–72. CrossRef
- Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Royal Stat Soc Series B 1995; 57: 289–300.
- Yeo GS, Siddle K. Attractin' more attention - new pieces in the obesity puzzle? Biochem J 2003; 376: e7–8. CrossRef
- Baranova A, Schlauch K, Gowder S et al. Microarray technology in the study of obesity and non-alcoholic fatty liver disease. Liver Int 2005; 25: 1091–6. CrossRef
- Sreekumar R, Rosado B, Rasmussen D et al. Hepatic gene expression in histologically progressive nonalcoholic steatohepatitis. Hepatology 2003; 38: 244–51. CrossRef
- Baranova A, Gowder SJ, Schlauch K. Gene expression of leptin, resistin, and adiponectin in the white adipose tissue of obese patients with non-alcoholic fatty liver disease and insulin resistance. Obes Surg 2006; 16: 1118–25. CrossRef
- Anty R, Bekri S, Luciani N et al. The inflammatory C-reactive protein is increased in both liver and adipose tissue in severely obese patients independently from metabolic syndrome, type 2 diabetes, and NASH. Am J Gastroenterol 2006; 101: 1824–33. CrossRef
- Roelen BA, Dijke P. Controlling mesenchymal stem cell differentiation by TGFBeta family members. J Orthop Sci 2003; 8: 740–8. CrossRef
- Fain JN, Tichansky DS, Madan AK. Transforming growth factor beta1 release by human adipose tissue is enhanced in obesity. Metabolism 2005; 54: 1546–51. CrossRef
- Smith DE, Hanna R, Della Friend et al. The soluble form of IL-1 receptor accessory protein enhances the ability of soluble type II IL-1 receptor to inhibit IL-1 action. Immunity 2003; 18: 87–96. CrossRef
- Poniachik J, Csendes A, Diaz JC et al. Increased production of IL-1alpha and TNFalpha in lipopolysaccharide-stimulated blood from obese patients with nonalcoholic fatty liver disease. Cytokine 2006; 33: 252–7. CrossRef
- Herlong JL, Scott TR. Positioning prostanoids of the D and J series in the immunopathogenic scheme. Immunol Lett 2006; 102: 121–31. CrossRef
- Perez S, Aspichueta P, Ochoa B et al. The 2-series prostaglandins suppress VLDL secretion in an inflammatory condition-dependent manner in primary rat hepatocytes. Biochim Biophys Acta 2006; 1761: 160–71.
- Wang Y, Zhang JS, Huang GC et al. Effects of adrenomedullin gene overexpression on biological behavior of hepatic stellate cells. World J Gastroenterol 2005; 11: 3549–53.
- Schattenberg JM, Singh R, Wang Y et al. JNK1 but not JNK2 promotes the development of steatohepatitis in mice. Hepatology 2006; 43: 163–72. CrossRef
- Falasca K, Ucciferri C, Dalessandro M et al. Cytokine patterns correlate with liver damage in patients with chronic hepatitis B and C. Ann Clin Lab Sci 2006; 36: 144–50.
- Gene Expression Patterns in Hepatic Tissue and Visceral Adipose Tissue of Patients with Non-Alcoholic Fatty Liver Disease
Volume 17, Issue 8 , pp 1111-1118
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Gene expression
- adipose tissue
- non-alcoholic fatty liver disease
- non-alcoholic steatohepatitis
- morbid obesity
- Industry Sectors
- Author Affiliations
- 1. Center for Liver Diseases, Inova Fairfax Hospital, Fairfax, VA, USA
- 2. Center for the Study of Genomics in Liver Diseases, Molecular and Microbiology Department, George Mason University, Fairfax, VA, USA
- 3. Department of Genetics and Genomics, Boston University School of Medicine, Boston, MA, USA
- 4. Center for Liver Diseases, Inova Fairfax Hospital, 3300 Gallows Road, Falls Church, VA, 22042, USA